PubMed · 12959352
Immunotherapy with anti-CD20 compounds.
Abstract
The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic lymphocytic leukaemia cells, and on all mature reactive B-cells. This review will summarise the modes of action of various reagents targeting CD20. Treatment results following their use in single and combination therapy for B-cell disorders are reviewed.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Christoph von Schilling. 2003. Immunotherapy with anti-CD20 compounds.. https://doi.org/10.1016/s1044-579x(03)00018-x
Cite the original work for its findings. Save a collection to share your selection of sources.